<DOC>
	<DOCNO>NCT02432066</DOCNO>
	<brief_summary>Attempts quit cigarette smoke often accompany negative mood problem attention memory . These effect , turn , may contribute smoke relapse . This exploratory/developmental project examine effect novel medication , GTS-21 , individual interested smoking cessation . It hypothesize GTS-21 reduce negative affect , improve cognition and/or reduce smoke relapse healthy adult men woman chronic cigarette smoker .</brief_summary>
	<brief_title>Effects GTS-21 Smoking Behavior Neurocognitive Functions</brief_title>
	<detailed_description>The project clinical trial assess effect GTS-21 ( Î±7 nicotinic receptor partial agonist ) smoking , mood , neurocognition , neurophysiology , small sample chronic smoker currently healthy interested smoking cessation . Using double-blind , placebo control , parallel group design , 54 ( 27 woman ) community smoker demonstrate readiness quit participate 7 week active trial . Subjects randomly assign active drug placebo group . Across study period , participant undergo repeat neurobehavioral testing , laboratory assessment cardiovascular liver function , provide weekly update regard smoke behavior , mood state side-effects .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>3- ( 2,4-dimethoxybenzylidene ) anabaseine</mesh_term>
	<criteria>Minimum 12 year education Must report typical daily smoke &gt; 10 cigarettes/day previous year Must report history least 3 year regular smoking Must provide carbon monoxide measure least 6.5 ppm Must report willingness quit smoke Participants engage behavioral and/or nicotine replacement therapy , assist quit effort , within previous 6 month . Must meet criterion substance dependence major psychiatric disorder . Must absent chronic medical condition might jeopardize health safety , confound data interpretation contraindicate administration compound act nAChR site . This list include disorder direct effect neurologic function ( e.g. , seizure disorder , transient ischemic event , chronic active hepatic disease ) , metabolic disorder ( e.g. , uncontrolled Type 2 diabetes ) , cardiovascular disease ( e.g. , hypertension , mitral valve compromise , tachycardia , irregular heart rate ) . Must smoke cigar , pipe hookahs use nicotine product cigarette Must report current use nicotine replacement therapy ( i.e. , occasion &gt; 4 h/week typical week , even use cessation aid ) Must use bupropion within previous year Must report past use ( regardless year ) varenicline Women may breastfeed , pregnant intend become pregnant study period</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Smoking</keyword>
	<keyword>Smoking Cessation</keyword>
</DOC>